[go: up one dir, main page]

ATE332708T1 - Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält - Google Patents

Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält

Info

Publication number
ATE332708T1
ATE332708T1 AT01941917T AT01941917T ATE332708T1 AT E332708 T1 ATE332708 T1 AT E332708T1 AT 01941917 T AT01941917 T AT 01941917T AT 01941917 T AT01941917 T AT 01941917T AT E332708 T1 ATE332708 T1 AT E332708T1
Authority
AT
Austria
Prior art keywords
pde4 inhibitor
cancer treatment
composition containing
treatment composition
antineoplastic agent
Prior art date
Application number
AT01941917T
Other languages
English (en)
Inventor
Stephen Thomas Davis
Inderjit Kumar Dev
Ronna Ellen Dornsife
John Gordon Gray
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE332708T1 publication Critical patent/ATE332708T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01941917T 2000-06-06 2001-06-04 Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält ATE332708T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20984600P 2000-06-06 2000-06-06

Publications (1)

Publication Number Publication Date
ATE332708T1 true ATE332708T1 (de) 2006-08-15

Family

ID=22780552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01941917T ATE332708T1 (de) 2000-06-06 2001-06-04 Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält

Country Status (7)

Country Link
EP (1) EP1289557B1 (de)
JP (1) JP2003535148A (de)
AT (1) ATE332708T1 (de)
AU (1) AU2001275228A1 (de)
DE (1) DE60121440T2 (de)
ES (1) ES2267778T3 (de)
WO (1) WO2001093909A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
KR101132545B1 (ko) 2001-02-14 2012-04-02 안트로제네시스 코포레이션 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
CA3046566A1 (en) 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placental stem cells for use in the treatment of neurological or renal diseases and disorders
MXPA03010672A (es) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Composicion para el tratamiento regenerativo de enfermedades del cartilago.
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
DK1908463T3 (da) * 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
KR20050000400A (ko) * 2002-04-12 2005-01-03 셀진 코포레이션 줄기 및 전구 세포 분화의 조절, 측정 및 이들의 용도
EP1571910A4 (de) 2002-11-26 2009-10-28 Anthrogenesis Corp Zytotherapeutika, zytotherapeutischeeinheiten und behandlungsverfahren, bei denen diese verwendet werden
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
WO2004062671A2 (en) * 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
CA2856662C (en) 2005-10-13 2017-09-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
PT2471906T (pt) 2005-12-29 2019-02-06 Celularity Inc Populações de células estaminais da placenta
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
CN101657206B (zh) 2007-02-12 2013-07-03 人类起源公司 利用胎盘干细胞治疗炎性疾病
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
EP3524253A1 (de) 2007-09-28 2019-08-14 Celularity, Inc. Tumorsuppression mit menschlichem plazentaperfusat und menschlichen natürlichen killerzellen eines zwischenproduktes aus der plazenta
MX339624B (es) 2008-08-20 2016-06-02 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
EP3284818B1 (de) 2010-01-26 2022-03-09 Celularity Inc. Behandlung von knochenbedingten karzinomen mit plazentastammzellen
RS55287B1 (sr) 2010-04-07 2017-03-31 Anthrogenesis Corp Angiogeneza korišćenjem matičnih ćelija iz placente
AU2011279201B2 (en) 2010-07-13 2016-01-21 Celularity Inc. Methods of generating natural killer cells
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells
WO2013188138A1 (en) * 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway
CN105142651A (zh) 2013-02-05 2015-12-09 人类起源公司 来自胎盘的自然杀伤细胞
US11052101B2 (en) 2019-03-25 2021-07-06 National Guard Health Affairs Methods for treating cancer using purine analogs by depleting intracellular ATP

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
JP2002500188A (ja) * 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション Ａ２ａアデノシンレセプター作動因子
CA2325080A1 (en) * 1998-03-28 1999-10-07 The Regents Of The University Of California Dfmo and sulindac combination in cancer chemoprevention
US6399649B1 (en) * 1998-09-24 2002-06-04 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
WO2001078651A2 (en) * 2000-04-12 2001-10-25 Cell Pathways, Inc. Method for treating neoplasmin with topoisomase i inhibitor
EP1188438A1 (de) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmazeutische Zusammensetzungen zur Vorbeugung oder Behandlung von mit IL-12 Überproduktion assozierten Erkrankungen

Also Published As

Publication number Publication date
EP1289557B1 (de) 2006-07-12
DE60121440T2 (de) 2007-06-28
ES2267778T3 (es) 2007-03-16
JP2003535148A (ja) 2003-11-25
WO2001093909A3 (en) 2002-12-05
DE60121440D1 (de) 2006-08-24
EP1289557A2 (de) 2003-03-12
WO2001093909A2 (en) 2001-12-13
AU2001275228A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
DE60121440D1 (de) Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
IL165267A (en) A drug comprising a mixture of an amino phospholipid antibody and a selected antiviral agent or antiviral vaccine conjugate, and an amino phospholipid binding antibody for use in the treatment or prevention of viral infections or diseases
CR7693A (es) Terapia de combinacion para enfermedades hiperproliferativas
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
PT932402E (pt) Metodo de utilizacao de inibidores de ciclooxigenase-2 no tratamento e prevencaode neoplasia
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR9814923A (pt) Método para tratamento de doença de alzheimer
WO2001051043A3 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
DE69940951D1 (de) Nd wachstumshemmende mittel
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
TR199901104T2 (xx) Farmas�tik bile�ikler.
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
BR9808221A (pt) Método de tratamento de tumor.
PT1140115E (pt) Complexos fosfolipidicos de proantocianidin a2 como agentes anti-ateroscleroticos
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties